Combined functional and morphological imaging of sarcomas: Significance for diagnostics and therapy monitoring;Kombinierte funktionelle und morphologische Bildgebung bei Sarkomen: Stellenwert für Diagnostik und Therapiemonitoring

Radiologe

Volumn 50, Issue 4, 2010, Pages 339-348

  Schramm, N ^a   Schlemmer, M ^a   Rist, C ^a   Issels, R ^a   Reiser, M F ^a   Berger, F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Hybrid; PET CT; Primary bone sarcoma; Soft tissue sarcoma

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; GERMANY; HUMAN; IMAGE SUBTRACTION; LUNG TUMOR; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SARCOMA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; FLUORODEOXYGLUCOSE F18; GERMANY; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77952675063     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-009-1973-1     Document Type: Article

References (28)

1. Arush MW, Israel O, Postovsky S et al (2007) Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 49:901-905
2. Bastiaannet E, Groen H, Jager PL et al (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30:83-101
3. Benz MR, Czernin J, Allen-Auerbach MS et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856-2863
4. Berger F, Winkler EC, Ruderer C et al (2009) Imaging of soft tissue sarcomas: standard approaches and new strategies. Chirurg 80:175-185
5. Bestic JM, Peterson JJ, Bancroft LW (2009) Use of FDG PET in staging, restaging, and assessment of therapy response in Ewing sarcoma. Radiographics 29:1487-1500
6. Bredella MA, Caputo GR, Steinbach LS (2002) Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 179:1145-1150
7. Daldrup-Link HE, Franzius C, Link TM et al (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 177:229-236
8. Eary JF, OSullivan F, Powitan Y et al (2002) Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 29:1149-1154
9. Evilevitch V, Weber WA, Tap WD et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715-720
10. Folpe AL, Lyles RH, Sprouse JT et al (2000) (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 6:1279-1287
11. Franzius C, Daldrup-Link HE, Sciuk J et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479-486
12. Franzius C, Schulte M, Hillmann A et al (2001) Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft tissue tumors. 3rd Interdisciplinary Consensus Conference PET in oncology: results of the Bone and Soft Tissue Study Group. Chirurg 72:1071-1077
13. Franzius C, Sciuk J, Daldrup-Link HE et al (2000) FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305-1311
14. Hain SF, ODoherty MJ, Bingham J et al (2003) Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl Med Commun 24:1139-1143
15. Hawkins DS, Schuetze SM, Butrynski JE et al (2005) [18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828-8834
16. Ioannidis JP, Lau J (2003) 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 44:717-724
17. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A et al (2008) Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie 31:107-112
18. Kole AC, Nieweg OE, van Ginkel RJ et al (1997) Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol 4:57-63
19. Kransdorf MJ, Jelinek JS, Moser RP Jr (1993) Imaging of soft tissue tumors. Radiol Clin North Am 31:359-372
20. Miles KA, Williams RE (2008) Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 8:81-86
21. Nair N, Ali A, Green AA et al (2000) Response of osteosarcoma to chemotherapy. Evaluation with F18 FDG-PET Scans. Clin Positron Imaging 3:79-83
22. Schulte M, Brecht-Krauss D, Heymer B et al (2000) Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 41:1695-1701
23. Schulte M, Brecht-Krauss D, Werner M et al (1999) Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40:1637-1643
24. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A et al (2005) Prognostic significance of preoperative [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 241:286-294
25. Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447-456
26. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
27. Viglianti BL, Lora-Michiels M, Poulson JM et al (2009) Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res 15:4993-5001
28. Weber WA, Figlin R (2007) Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 48 [suppl 1]:36S-44S